Engineering of stable neuromedin-U (NMU) octapeptide analogues and related dual-agonist peptides for use in diabetes and obesity therapy

These scholarships will cover full-time PhD tuition fees for three years (subject to satisfactory academic performance) and will provide a £900 per annum research training support grant (RTSG) to help support the PhD researcher.

Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year (or part-time equivalent) are NOT eligible to apply for an award.

Please note: you will automatically be entered into the competition for the Full Award, unless you state otherwise in your application.

The scholarship will cover tuition fees at the Home rate and a maintenance allowance of £19,000 (tbc) per annum for three years (subject to satisfactory academic performance).

This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.

[1] O'Harte FPM, Bockman CS, Abel PW, Conlon JM. (1991) Isolation, structural characterization and pharmacological activity of dog neuromedin U. Peptides 12(1):11-15.
[2] O'Harte FPM, Bockman CS, Zeng W, Abel PW, Harvey S, Conlon JM. (1991) Primary structure and pharmacological activity of a nonapeptide related to neuromedin U isolated from chicken intestine. Peptides 12(4):809-812.
[3] Martinez VG and O’Driscoll L. (2015) Neuromedin U: a multifunctional neuropeptide with pleiotropic roles. Clin. Chem. 61,471–482.
[4] Howard AD, Wang R, Pong S-S, Mellin TN, Strack A, Guan X.-M, et al., (2000) Identification of receptors for neuromedin U and its role in feeding. Nature 406,70–74.
[5] Gevaert B, Wynendaele E, Stalmans S, Bracke N, D’Hondt M, Smolders I, van Eeckhaut A and De Spiegeleer B. (2016) Blood-brain barrier transport kinetics of the neuromedin peptides NMU,NMN, NMB and NT. Neuropharmacology 107,460–47010.
[6] Kowalski TJ, Spar BD, Markowitz L, Maguire M, Golovko A, Yang S, et al., (2005) Transgenic over expression of neuromedin U promotes leanness and hypophagiain mice. J. Endocrinol. 185,151–164.
[7] Zeng H, Gragerov A, Hohmann JG, Pavlova MN, Schimpf BA, Xu H, et al., (2006) Neuromedin U receptor 2-deficient mice display differentialresponses in sensory perception, stress, and feeding. Mol. Cell. Biol. 26,9352–9363.
[8] Peier A, Kosinski J, Cox-York K, Qian Y, Desai K, Feng Y, et al., (2009) The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2). Endocrinology 150,3101–3109.
[9] Peier AM, Desai K, Hubert J, Du X, Yang L, Qian Y, et al., (2011) Effects of peripherally administered neuromedin U on energy and glucose homeostasis. Endocrinology 152,2644–2654.
[10] Alfa RW, Park S, Skelly KR, Poffenberger G, Jain N, Gu X, et al., (2015) Suppression of insulin production and secretion by a decretin hormone. Cell Metab. 21,323–334.
[11] Kaczmarek P, Malendowicz LK, Fabis M, Ziolkowska A, Pruszynska-Oszmalek E, Sassek M, et al., (2009) Does somatostatin confer insulinostatic effects of neuromedin U in the rat pancreas? Pancreas 38,208–212.
[12] Kuhre RE, Christiansen CB, Ghiasi SM, Gabe MBN, Skat-Rørdam PA, Modvig IM, et al., (2018) Neuromedin U does not act as a decretin in rats. 29(3),719-726.
[13] Mondal MS, Date Y, Murakami N, Toshinai K, Shimbara T, Kangawa K and Nakazato M. (2003) Neuromedin U acts in the central nervous system to inhibit gastric acid secretion via CRH system. Am. J. Physiol. Gastrointest. Liver Physiol. 284,G963–G969.
[14] Dalbøge LS, Pedersen SL, Secher T, Holst B, Vrang N and Jelsing J. (2015) Neuromedin U inhibits food intake partly by inhibiting gastric emptying. Peptides 69,56–65.